Older or unfit patients with mantle cell lymphoma (MCL) often do not tolerate intensive first-line therapies due to poor tolerability.¹ In such cases, bendamustine-rituximab (BR) combination is the most commonly used first-line regimen.¹ While adding Bruton's tyrosine kinase inhibitors (BTKi), such as ibrutinib, to BR has demonstrated improved progression-free survival (PFS), this approach has not translated into an overall survival (OS) benefit, primarily due to toxicity.¹

Mantle cell lymphoma (MCL) is a B cell malignancy that is typically clinically aggressive with a poor prognosis.¹ When MCL patients progress into relapsed/refractory MCL (RRMCL), the median overall survival (OS) is usually reduced to around 1 year. Currently, three Bruton’s tyrosine kinase inhibitor

Mantle cell lymphoma (MCL) is an uncommon but aggressive subtype of lymphoid malignancy, generally considered to have a poor prognosis.¹ Although the disease responds well to initial treatment, relapse will inevitably occur,¹